Literature DB >> 29607652

Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.

Prema Menezes1,2,3, Katie Mollan3, Erin Hoffman1, Zimeng Xie4, Jennifer Wills1, Cheryl Marcus1, John Rublein5, Michael Hudgens3,4, Joseph J Eron1,2,3.   

Abstract

Benefits of switching to a single-tablet regimen (STR) of emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) in virologically suppressed antiretroviral treatment (ART) experienced HIV-positive women include pregnancy category B rating and lack of clinically significant drug interactions between RPV and oral contraceptives. Unfortunately, studies involving switching to FTC/RPV/TDF enrolled fewer than 25% women. We undertook this 48-week study to assess the ability of virologically suppressed HIV-positive women switching to RPV STR to remain virologically suppressed and comply with the caloric intake requirement. HIV-positive women on ART with viral load <50 c/mL for 6 months before study entry and no known resistance to FTC, TDF, or RPV were enrolled and switched to STR RPV/FTC/TDF. Caloric intake (≥400 kcal) compliance and concurrency with oral STR RPV/FTC/TDF were evaluated with a 3-day food diary, which was validated by obtaining participant's caloric consumption through phone calls on randomly chosen dates. For each 3-day food diary, the daily median caloric intake and median value for each macronutrient consumed concurrent with FTC/RPV/TDF were computed. Medication adherence was measured using a visual analog scale. We enrolled 33 women, 73% of whom were African American. At week 48, virologic suppression (HIV RNA <40 c/mL) was maintained in 96% of women, including those (n = 4) who reported imperfect ART adherence. The daily median caloric intake concurrent with FTC/RPV/TDF was 820 kcal by food diary and 677 kcal by random phone call. Median kcal intake (food diary) did not change significantly from baseline (684 kcal) to week 48 (820 kcal); median change 102 kcal, p = .15. Women who reported noncompliance with a ≥400 kcal meal did not experience virologic failure. Significant concordance between caloric adherence and virologic suppression was not detected. Our study demonstrated that HIV-positive women who switched to STR FTC/RPV/TDF continued to experience virologic suppression and were readily able to comply with the recommended caloric intake requirement.

Entities:  

Keywords:  HIV; HIV-positive women; rilpivirine; single-tablet regimen; switch study

Mesh:

Substances:

Year:  2018        PMID: 29607652      PMCID: PMC5994664          DOI: 10.1089/AID.2016.0311

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.

Authors:  Frank J Palella; Martin Fisher; Pablo Tebas; Brian Gazzard; Peter Ruane; Jan Van Lunzen; David Shamblaw; Jason Flamm; Ramin Ebrahimi; Danielle Porter; Kirsten White; Jason Hindman; Elizabeth Elbert; Shampa De-Oertel; Todd Fralich
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

2.  Fructose and satiety.

Authors:  Timothy H Moran
Journal:  J Nutr       Date:  2009-04-29       Impact factor: 4.798

3.  Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

Authors:  Anthony M Mills; Calvin Cohen; Edwin Dejesus; Cynthia Brinson; Scott Williams; Kitty L Yale; Srini Ramanathan; Maggie H Wang; Kirsten White; Susan K Chuck; Andrew K Cheng
Journal:  HIV Clin Trials       Date:  2013 Sep-Oct

4.  Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.

Authors:  Nathan Ford; Janice Lee; Isabelle Andrieux-Meyer; Alexandra Calmy
Journal:  HIV AIDS (Auckl)       Date:  2011-04-28

5.  Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.

Authors:  Carmela Pinnetti; Simona Di Giambenedetto; Franco Maggiolo; Patrizia Lorenzini; Massimiliano Fabbiani; Chiara Tommasi; Alessandra Latini; Adriana Ammassari; Laura Loiacono; Gaetana Sterrantino; Rita Bellagamba; Evangelo Boumis; Andrea Antinori; Mauro Zaccarelli
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

  5 in total
  1 in total

1.  [Value of three-dimensional speckle-tracking imaging in evaluating left ventricular systolic function and its correlation with peripheral arterial elasticity in children with simple obesity: a prospective study].

Authors:  Li Zhou; Shu-Xia Wang; Fang Wang; Wei Cao; Ting-Ting Wang; Jing-Jing Ye; Li-Sha Na; Hai-Ping Zhao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.